Efficacy and Safety of Mecloderm Cream vs. Lotricomb Cream vs. Vehicle in Moderate to Severely Inflamed Cutaneous Candidiasis: A Double-Blind, Randomized Study

The primary objective of this double-blind, randomized clinical study is to compare the **efficacy** and **safety** of Mecloderm® Cream (Test) versus Lotricomb® Cream (Reference) and a Vehicle in patients with moderate to severely inflamed **candidiasis** of the skin. This study is clinically relevant as it aims to determine the most effective and safe treatment option for managing this condition, which is characterized by significant inflammation and discomfort. The study does not specify any secondary objectives.

The clinical trial involves participants diagnosed with **moderate to severely inflamed candidiasis of the skin**. The study population includes both male and female subjects, with an age range that encompasses adults and adolescents. The trial also considers vulnerable populations, although specific details regarding the selection process or lifestyle considerations such as diet, physical activity, or habits are not provided. The sponsor has not disclosed the total number of participants involved in the study. Key inclusion or exclusion criteria have not been specified in the available data.

The clinical trial is designed as a **double-blind**, randomized, controlled study to evaluate the efficacy and safety of Mecloderm® Cream compared to Lotricomb® Cream and a vehicle in patients with moderate to severely inflamed **candidiasis** of the skin. The trial is expected to span from October 18, 2021, to June 2, 2025, encompassing a comprehensive evaluation period. Participants will be randomly assigned to one of the three treatment groups, ensuring that neither the participants nor the investigators are aware of the specific treatment allocations, thus maintaining the integrity of the **double-blind** methodology.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful screening, participants will undergo a series of follow-up visits at regular intervals to monitor treatment efficacy and safety. These visits will include clinical assessments, laboratory tests, and adverse event monitoring. The end-of-study visit will mark the conclusion of the participant's involvement, where final evaluations will be conducted to gather comprehensive data on the treatment outcomes.

The expected length of participant involvement in the study is determined by the trial's duration, with individual participation lasting until the end-of-study visit unless early termination criteria are met. Conditions that may lead to early termination from the study include significant adverse events, withdrawal of consent, or any other medical or ethical reasons deemed necessary by the investigators. The trial's design and procedures are structured to ensure rigorous data collection and analysis, contributing to the understanding of treatment efficacy and safety for moderate to severely inflamed **candidiasis** of the skin.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment protocols accurately.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under phase 5, indicating a focus on post-marketing surveillance to gather additional information on the drug's effectiveness and safety in a larger population. The trial is scheduled to commence recruitment on October 18, 2021, with an estimated completion date of June 2, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely employ standard methodologies appropriate for its phase to measure and analyze outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, depending on the nature of the medical condition under investigation. The trial will adhere to rigorous data collection and analysis protocols to ensure the reliability and validity of the efficacy assessments.